← FDA DRUG APPROVALS
FDA ANDA · ANDA208823
OSELTAMIVIR PHOSPHATE FOR ORAL SUSPENSION
oseltamivir phosphate
Sponsor: ALVOGEN
APPLICATION
ANDA208823
TYPE
ANDA
ORIGINAL APPROVAL
2017-10-31
LATEST ACTION
2021-12-16
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription
Products
OSELTAMIVIR PHOSPHATEPrescription
OSELTAMIVIR PHOSPHATE EQ 6MG BASE/ML · FOR SUSPENSION · ORAL
Approval history
2021-12-16Labeling · Supplement 2 · standardAP
2021-12-16Labeling · Supplement 7 · standardAP
2021-12-16Labeling · Supplement 5 · standardAP
2017-10-31UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.